(Circulation: Cardiovascular Interventions) The DynamX coronary bioadaptor continued to perform well 3 years into the BIOADAPTOR trial, as announced by Elixir Medical. CytoSorbents shared more ...

David Deeds is in financial trouble, and he's hoping a federal court in Texas can help get him out of it. Deeds, who is 62 and owes tens of thousands of dollars in medical debt from cancer ...

Elixir Medical’s DynamX [Image courtesy of Elixir Medical] Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system.

Meanwhile, innovators like Meril, Elixir Medical and more provided their own clinical findings supporting their technologies, too. Johnson & Johnson MedTech‘s Shockwave Medical unit shared ...

BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX ® bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies ...

Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient ...

Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient ...

Morningstar brands and products Company Portfolio ...

"With these results, we are pleased to demonstrate that restoring hemodynamic modulation of the artery translates to lasting clinical outcomes, elevating the level of care for patients,” said Motasim ...